Since PARP1 is overactivated in many cancers, such as ovarian, breast, and oral cancers, impairing the DNA damage repair (DDR) pathway of cancer cells by inhibiting PARP1 activity turned out to be a promising cancer treatment strategy (4), as evidenced in the clinical settings where PARP1 inhibitors are administered to patients who have breast or ovarian cancer with BRAC1/2 mutation (HR deficiency) (5). This evidence concerns the gene PARP1 and ovarian carcinoma.